Paper Details

  1. Home
  2. Paper Details

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.

Author: , Barrett-ConnorElizabeth L, BauerDouglas C, BlackDennis M, EnsrudKristine E, FeldsteinAdrianne, HaskellWilliam L, HochbergMarc C, LombardiAntonio, SantoraArthur C, SchwartzAnn, SuryawanshiShailaja, TornerJames C

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study shows that the benefits of alendronate, a drug used to treat osteoporosis, can last even after stopping the medication. Women who continued taking the drug for three years had better bone health than those who stopped, but even those who stopped still had better bone health than before they started.
Paper Details　
Original Abstract of the Article :
To determine the effects of continuation versus discontinuation of alendronate on BMD and markers of bone turnover, we conducted an extension trial in which 1099 older women who received alendronate in the FIT were re-randomized to alendronate or placebo. Compared with women who stopped alendronate,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1359/JBMR.040326

データ提供：米国国立医学図書館（NLM）

Alendronate: Long-Term Effects on Bone Mineral Density

Alendronate, a medication used to treat osteoporosis, plays a crucial role in improving bone mineral density (BMD) and reducing fracture risk. This extension trial, conducted as part of the Fracture Intervention Trial (FIT), investigates the long-term effects of continuing or discontinuing alendronate treatment in women with low BMD.

Continued Alendronate Benefits Bone Health: A Lasting Impact

The findings demonstrate that continuing alendronate for 3 years after initial treatment results in sustained improvements in BMD and bone turnover markers. Even after discontinuing alendronate, participants who had received the drug during the initial FIT phase exhibited higher BMD and reduced bone turnover compared to baseline values, indicating a lasting positive impact on bone health.

A Desert of Bone Loss: Protecting Bone Health with Long-Term Strategies

The study highlights the importance of long-term strategies for managing bone health. Alendronate appears to have a lasting positive effect on BMD, suggesting that continued treatment may be beneficial for maintaining optimal bone health. It’s like navigating a desert – we need to plan ahead and implement long-term strategies to sustain our health and well-being.

Dr. Camel's Conclusion

This extension trial provides valuable insights into the long-term effects of alendronate on bone health. The researchers' findings underscore the importance of continuing alendronate treatment for maintaining optimal bone mineral density and reducing fracture risk. The study serves as a reminder that, just as a desert traveler must diligently plan for their journey, we must take proactive steps to safeguard our bone health.
Date :
  1. Date Completed 2005-03-16
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

15231012

DOI: Digital Object Identifier

10.1359/JBMR.040326

Related Literature

Article Analysis
・Effects of alendronate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.